International Heart Journal · 2009 · 13 citations · 17 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyClinical PharmacologyPharmacodynamicsBlood Pressure ControlBlood Pressure ManagementDiuretic TherapyHypertension ManagementHypertension PharmacotherapyAmbulatory Blood Pressure ControlAngiotensin Ii Receptor BlockersAntihypertensive Drug TherapyAntihypertensive PharmacologyAntihypertensive TreatmentPartial Agonist EfficacyPeroxisome Proliferator-activated Receptor SignalingPeroxisome Proliferator-activated Receptors
Among angiotensin receptor blockers (ARBs), telmisartan is suggested to function as a partial agonist of peroxisome proliferator-activated receptor-gamma (PPAR gamma) and to improve lipid and glucose metabolism. Clinical benefits of telmisartan over other ARBs may be apparent in combination with diuretics, which have harmful influences on lipid and glucose metabolism. In the present study, 21 patients treated with mild to moderate hypertension (13 women and 8 men aged 63.1 +/- 11.6 years) underwent a 24-week treatment period with telmisartan 40 mg and HCTZ 12.5 mg once daily, or a 24-week treatment period with losartan 50 mg and HCTZ 12.5 mg once daily, without a wash-out period, in a quasi-randomized cross-over manner. Their ambulatory blood pressure and metabolic parameters were measured after the 2 treatment periods. Ambulatory systolic and diastolic blood pressures did not differ significantly between the 2 treatment periods during 24 hours, daytime, night-time, and early-morning hours (06:00-08:00). Serum uric acid was insignificantly higher in the treatment period with telmisartan/HCTZ than in the treatment period with losartan/HCTZ (P = 0.086). Although serum total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol did not differ significantly, serum triglycerides were slightly higher in the treatment period with telmisartan/HCTZ than in the treatment period with losartan/HCTZ (P = 0.060). Parameters of glucose metabolism did not differ significantly between the 2 treatment periods. In conclusion, antihypertensive efficacy was similar between the 2 regimens throughout 24 hours, despite different elimination half-lives of telmisartan and losartan. Although telmisartan is suggested to function as a partial agonist of PPARgamma, no clinical benefit was found in combination with HCTZ with respect to lipid and glucose metabolism.
17
2007 Guidelines for the Management of Arterial Hypertension
Giuseppe Mancia, Guy De Backer, Anna F. Dominiczak et al. · Journal of Hypertension · 2007 · 5.8K citations
2013 ESH/ESC Guidelines for the management of arterial hypertension
Giuseppe Mancia, Robert Fagard, Krzysztof Narkiewicz et al. · Journal of Hypertension · 2013 · 5.7K citations